繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 综合药讯 >> Beyaz复方片剂-在美国获批准上市

Beyaz复方片剂-在美国获批准上市

2011-01-13 17:14:32  作者:新特药房  来源:中国新特药网天津分站  浏览次数:334  文字大小:【】【】【
简介: 近日,美国食品药品监督管理局批准拜耳公司申请的联用避孕药Beyaz片剂上市,该药物是雌激素(戊酸雌二醇)和孕激素(地诺孕素)及叶酸(添加左甲基四氢叶酸钙0.451mg)的联用药物。 左甲基四氢叶酸钙是叶酸代 ...

Beyaz is claimed to be the first and only oral contraceptive (OC) approved to raise folate levels in women who choose an OC for birth control.

In these women, Beyaz raises folate levels for the purpose of reducing the risk of a neural tube defect (NTD) in a pregnancy conceived while taking Beyaz or shortly after discontinuing it. 

It combines the hormone ingredients in the birth control pill YAZ (drospirenone 3 mg/ ethinyl estradiol 20 mcg) with 451 mcg levomefolate calcium, which is a B vitamin.

Manufacturer:

Bayer HealthCare

Pharmacological Class:

Combination oral contraceptive (progestin + estrogen) + folate.

Active Ingredient(s):

Drospirenone 3mg + ethinyl estradiol (as betadex clathrate) 20micrograms + levomefolate calcium 0.451mg (24 pink tabs); levomefolate calcium 0.451mg (4 light orange tablets).

Indication(s):

Oral contraception. Premenstrual dysphoric disorder (PMDD) in women who choose an oral contraceptive for contraception. Moderate acne vulgaris in women ≥14 years old who choose an oral contraceptive for contraception. To raise folate levels in women who choose to use an oral contraceptive for contraception.

Pharmacology:

Combined oral contraceptives ­reduce the risk of pregnancy primarily by ­inhibiting ovulation. This product combines drospirenone, an analogue of spironolactone that has both antimineralocorticoid and anti­androgenic activities, with an estrogen plus ­folate supplementation. Levomefolate calcium 0.451mg (equivalent to folic acid 0.4mg) is included for reducing the risk of neural tube defects in a pregnancy conceived while taking the product or shortly after discontinuing the product.

Legal Classification:

Rx

Adults:

1 tablet daily for 28 days; repeat. Take at the same time daily. Use Day 1 or Sunday start for 1st cycle; use backup method for first 7 days. Allow at least 4 weeks postpartum, if not breastfeeding, to begin cycle.

Children:

Premenarchal: not recommended.

Contraindication(s):

Renal impairment. Adrenal insufficiency. High risk of arterial or venous thrombotic disease (eg, smokers or migraineurs over age 35, history of DVT or thromboembolism, cerebrovascular or coronary artery disease, thrombogenic valvular disease, atrial fibrillation, subacute bacterial endocarditis, hypercoagulopathies, uncontrolled hypertension, diabetes with vascular disease, headaches with focal neurologic symptoms). Breast or other estrogen or progestin-sensitive neoplasms. Hepatic disease or tumors. Undiagnosed abnormal uterine bleeding. Pregnancy (Cat.X).

Warnings/Precautions:

Discontinue if thrombotic event, unexplained visual changes, or jaundice occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Hyperkalemia or risk thereof. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Pregnancy-related cholestasis. Depression. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Monitor blood pressure. Nursing mothers: not recommended.

Interaction(s):

May potentiate drugs that can cause hyperkalemia in chronic use (eg, ACE ­inhibitors, ARBs, NSAIDs, K+ sparing diuretics, K+ supplementation, heparin, aldosterone blockers) (check serum K+ during 1st cycle). May be antagonized by CPY3A4 or other enzyme inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenyt­oin, rifampin, St. John’s wort, topiramate) (use backup contraception). May be affected by pro­tease inhibitors, acetaminophen, ascorbic acid, itraconazole, ketoconazole. May antagonize lam­o­tri­gine. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). May need dose adjustment of thyroid hor­mones. May mask vitamin B12 deficiency (folate).

Adverse Reaction(s):

Irregular uterine bleeding, headache, nausea, mastodynia, fatigue, irrita­bility, decreased libido, increased weight, fluid retention, mood changes; others (see literature).

Notes:

Use backup method or restart if 2 or more pink pills are missed (see literature); consider severe nausea/diarrhea as missed pill. Continue folate supplementation if pills are discontinued due to pregnancy.

How Supplied:

Packs—3 (3x28 day cycles)

近日,美国食品药品监督管理局批准拜耳公司申请的联用避孕药Beyaz片剂上市,该药物是雌激素(戊酸雌二醇)和孕激素(地诺孕素)及叶酸(添加左甲基四氢叶酸钙0.451mg)的联用药物。

左甲基四氢叶酸钙是叶酸代谢物,是产生和维持人体内新细胞的水溶性维生素B,妇女在怀孕分娩期间叶酸缺乏会引起神经管缺陷症(如脊柱裂)。
Beyaz是在YAZ基础上开发的,具有与之相同剂量的雌激素(戊酸雌二醇)和孕激素(地诺孕素),FDA批准其适应症有:避孕;治疗妇女因服用口服避孕药而引发经前焦虑症(PMDD);对于14岁以上使用口服避孕药避孕女性,可用于治疗的中度痤疮。
除了YAZ的适应症之外,Beyaz还可以在避孕的同时提高用药妇女的叶酸水平,防止用药或停药后怀孕时因叶酸不足而引起的脊柱裂。
对Beyaz的基本药效进行了一项多中心、双盲、随机的研究,该实验在379名年龄18-40岁的健康妇女之间进行,单独用药Beyaz或YAZ24周,使用Beyaz组的叶酸水平明显提高。在德国进行的临床试验中,停药Beyaz数周后叶酸仍能维持较高水平。对避孕、经前焦虑症以及暗疮等症的治疗安全性及有效性数据来源于YAZ的临床研究。
常见的不良反应报道有:子宫不规则出血、恶心、乳房压痛以及头疼等,其他较严重的副作用有血栓及肝脏疾病,35岁吸烟女性不可使用该药,否则会引起严重心血管疾病风险。Beyaz的副作用与YAZ相同,安全性问题也与之无异。


制造商
拜耳医药保健

药理分类:
复方口服避孕药(孕激素雌激素)的叶酸。

活性成分(补):
为3mg屈螺酮炔雌醇(如betadex包合物)20micrograms levomefolate钙0.451mg(24粉红色标签); levomefolate钙0.451mg(4浅橙粒)。

指示(补):
口服避孕药。经前烦躁症(PMDD的)的妇女谁选择口服避孕药避孕。中度痤疮的妇女≥14岁谁选择口服避孕药避孕。为了提高妇女谁选择使用口服避孕药避孕的叶酸水平。

药理作用:
复方口服避孕药通过抑制排卵减少主要是对怀孕的危险。该产品结合了屈螺酮,安体舒通有一个既antimineralocorticoid和抗雄激素与雌激素加活动补充叶酸,模拟。 Levomefolate钙0.451mg(相当于叶酸为0.4mg)包括减少神经管缺陷的一个设想,而怀孕的危险产品或服用后不久停止该产品。


法律分类:
接收

成人:
1片,28天;重复。在同一时间以每天。使用第1天或周日开始第一周期;使用第7天备份方法。允许产后至少4周,如果不是母乳喂养,开始循环。

儿童:
Premenarchal:不推荐。

禁忌(补):
肾功能损害。肾上腺功能不全。高风险的动脉或静脉血栓性疾病(如吸烟或偏头痛患者年龄超过35岁,深静脉血栓形成或栓塞,脑血管或冠状动脉疾病,血栓形成瓣膜病,心房颤动的历史,亚急性细菌性心内膜炎,hypercoagulopathies,不受控制高血压,糖尿病血管病变,局灶性神经系统症状,头痛)。乳腺癌雌激素或孕激素或其他敏感的肿瘤。肝脏疾病或肿瘤。未确诊的子宫异常出血。妊娠(Cat.X)。

警告/注意事项:
如果停止血栓性事件,原因不明的视力改变,或出现黄疸,并至少有4周前通过2后的血栓风险增加有关手术星期。高钾血症或风险单位。糖尿病。糖尿病前期。不受控制的高脂血症。妊娠有关的胆汁淤积。抑郁症。评估重大变化,头痛,不规则子宫出血,闭经。监测血压。哺乳母亲:不推荐。

互动(补):
会增强药物,长期使用可引起(如ACE抑制剂,ARB类,NSAIDs类药物,钾利尿剂,钾补充剂,肝素,醛固酮阻断剂)(检查在第一个周期血清K)高钾血症。可拮抗CPY3A4或其他酶诱导剂(如巴比妥酸盐,波生坦,卡马西平,非氨酯,灰黄霉素,奥卡西平,苯妥英,利福平,圣约翰草,托吡酯)(使用备份避孕)。可能受蛋白酶抑制剂,对乙酰氨基酚,抗坏血酸,伊曲康唑,酮康唑。林可拮抗邻三gine。可能会影响实验室检查(如凝血因子,血脂,血糖耐受性,结合蛋白)。可能需要剂量甲状腺贺- mones调整。可能会掩盖维生素B12缺乏(叶酸)。
不良反应(补):
子宫不规则出血,头痛,恶心,mastodynia,疲劳,易怒,性欲降低,体重增加,水肿,情绪变化,其他的(见文献)。
注释:
使用备份方法或重新启动,如果2个或更多的粉红色药丸被错过(见文献),考虑为严重的恶心错过丸/腹泻。如果继续补充叶酸药丸已停产,由于怀孕。

如何提供:
包- 3(3x28天的周期)

最后更新:
2010年11月4号

责任编辑:admin


相关文章
LO LOESTRIN FE(复方口服避孕药)
新型复方口服避孕药-屈螺酮炔雌醇片(SAFYRAL)获批上市
 

最新文章

更多

· 无水酒精注射液(DEHYDR...
· DEHYDRATED ALCOHOL(无...
· 除铁能注射剂DESFERAL(D...
· ALBUMINAR IV SOLUTION(...
· Dantrium Intravenous I...
· Bunavail(盐酸丁丙诺啡...
· Dyloject(diclofenac so...
· THAM SOLUTION(trometha...
· THAM Injection SET(Tr...
· 首个基因新药Glybera注射...

推荐文章

更多

· 无水酒精注射液(DEHYDR...
· DEHYDRATED ALCOHOL(无...
· 除铁能注射剂DESFERAL(D...
· ALBUMINAR IV SOLUTION(...
· Dantrium Intravenous I...
· Bunavail(盐酸丁丙诺啡...
· Dyloject(diclofenac so...
· THAM SOLUTION(trometha...
· THAM Injection SET(Tr...
· 首个基因新药Glybera注射...

热点文章

更多

· 除铁能注射剂DESFERAL(D...
· DEHYDRATED ALCOHOL(无...
· 无水酒精注射液(DEHYDR...